检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:陈健[1] 朱卫华[1] 施民新[1] 林兰[1] 刘继斌[1]
出 处:《现代肿瘤医学》2015年第20期2936-2939,共4页Journal of Modern Oncology
基 金:南通市科技计划项目(编号:HS2011006)
摘 要:目的:研究着色性干皮病基因(ERCC2/XPD)和 X 线修复交叉互补基因1(XRCC1)单核苷酸多态性与晚期食管癌铂类药物化疗敏感性关系。方法:采用聚合酶链反应-限制性片段长度多态性(PCR -RFLP)方法检测80例以铂类药物为主要化疗方案的食管癌患者和 CC2/XPD Lys751Gln 和 XRCC1 Arg399Gln 基因多态性,应用非条件 Logistic 回归计算 OR 值及95%CI,分析不同基因型与化疗疗效的关系。结果:80例晚期食管癌患者中,ERCC2/XPD 751基因 Lys/Lys、Lys/Gln、Gln/Gln 基因型的分布频率分别为58例(72.5%)、17例(21.3%)和5例(6.3%);XRCC1399基因 Arg /Arg、Arg /Gln、Gln /Gln 基因型的分布频率分别为43例(53.8%)、28例(35.0%)和9例(11.3%);化疗后临床获益率为52.5%,其中完全缓解(CR)、部分缓解(PR)、稳定(SD)和进展(PD)患者分别为0例、29例(36.3%)、23例(28.8%)和28例(35.0%),ERCC2/XPD 基因型多态性与化疗敏感性具有相关性(OR =3.723,95%CI =1.613~12.532,P <0.01);发现至少携带1个 XRCC1399Arg 等位基因型患者的化疗敏感性是 Gln /Gln 基因型的3.62倍(校正 OR =3.62,95%CI=1.19~11.43,P <0.01)。结论:ERCC2/XPD 和 XRCC1基因多态性可能与晚期食管癌铂类药物化疗敏感性有一定关系。Objective:To evaluate the relationship of DNA repair gene ERCC2 /XPD and XRCC1 polymorphisms with chemosensitivity to platinum -based chemotherapy in advanced esophageal squamous cell carcinoma.Methods:ERCC2 /XPD Lys751Gln and XRCC1 Arg399Gln gene polymorphisms were detectd by the polymerase chain reaction-restriction fragment length polymorphism (PCR -RFLP)assays in 80 patients with advanced esophageal squamous cell carcinoma who received platinum -based chemotherapy.Unconditional logistic regression model was used to ana-lyze the assoc iation between ERCC2 /XPD and XRCC1 gene polymorphisms and chemosensitivity.Results:The fre-quency for ERCC2 /XPD 751 genes Lys /Lys,Lys /Gln,Gln /Gln genotypes were 5 8 cases (72 .5 %),17 cases (21.3%)and 5 cases(6.3%)and XRCC1 399 genes Arg/Arg,Arg/Gln,Gln/Gln genotypes frequencies were 43 cases(53.8%),28 cases(35.0%)and 9 cases(11.3%).The overall response rate was 52.5%,including 29 cases with partial reponse,23 cases with stable disease,and 28 cases with progression disease.ERCC2 /XPD gene polymor-phisms correlated with sensitivity to chemotherapy(OR =3.723,95%CI =1.613 ~12.532,P <0.01).The XRCC1 399Arg allele carriers had higher chemosensitivity to platinum than the cases presenting with Gln/Gln genotype (OR =3.62,95%CI =1.19 ~11.43,P <0.01).Conclusion:ERCC2 /XPD and XRCC1gene polymorph isms may be associated with chemosensitivity to platinum -based chemotherapy in advanced esophageal carcinoma.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.38